{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:25:40Z","timestamp":1793190340299,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>An update of a systematic review and meta-analysis of the risk of arrhythmias and their subtypes in type 2 diabetic patients receiving glucagon-like peptide 1 receptor agonist (GLP-1RA) medication according to data from the Cardiovascular Outcome Trial(CVOT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Randomized controlled trials (RCT) on GLP-1RA therapy and cardiovascular outcomes in type 2 diabetes mellitus patients published in full-text journal databases such as MEDLINE (via PubMed), Embase, Clinical Trials.gov, and the Cochrane Library from establishment to March 1, 2022 were searched. We assessed the quality of individual studies by the Cochrane risk-of-bias algorithm. RevMan 5.4.1 software was use for calculating meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 60,081 randomized participants were included in the data of these 8 GLP-1RA cardiovascular outcomes trials. Pooled analysis reported no significant effect on total arrhythmia [RR=0.96, 95% CI (0.96, 1.05), <jats:italic>p<\/jats:italic> =0.36], and its subtypes such as atrial fibrillation [RR=0.96, 95% CI (0.86, 1.07), <jats:italic>p<\/jats:italic> =0.43], atrial flutter [RR= 0.82, 95% CI (0.57, 1.19), <jats:italic>p<\/jats:italic> =0.30], atrial tachycardia [RR=0.64, 95% CI (0.20, 2.01), <jats:italic>p<\/jats:italic> =0.44)], sinoatrial node dysfunction [RR=0.74, 95% CI (0.44, 1.25), <jats:italic>p<\/jats:italic>\u00a0=0.26], ventricular preterm systole [RR=1.42, 95% CI (0.62, 3.26), <jats:italic>p<\/jats:italic> =0.41], second degree AV block [RR=0.96, 95% CI (0.53, 1.72), <jats:italic>p<\/jats:italic> =0.88], complete AV block [RR=0.75, 95% CI (0.49, 1.17), <jats:italic>p<\/jats:italic> =0.21], ventricular fibrillation [RR=1.00, 95% CI (0.50, 2.02), <jats:italic>p<\/jats:italic> =1.00], ventricular tachycardia [RR=1.37, 95% CI (0.91, 2.08), <jats:italic>p<\/jats:italic>\u00a0=0.13] from treatment with GLP-1RA versus placebo. However, the risk of hypoglycemia was reduced by about 30% [RR=0.70, 95% CI (0.57, 0.87), <jats:italic>p<\/jats:italic>=0.001] and the risk of pneumonia by about 25% [RR=0.85, 95% CI (0.75, 0.97), <jats:italic>p<\/jats:italic>=0.01], both statistically significant differences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In type 2 diabetic patients, treatment with GLP-1RA has no significant effect on the risk of major arrhythmias but significantly reduces the risk of hypoglycemia and pneumonia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.910256","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T09:41:27Z","timestamp":1660210887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Jinjing","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13512","article-title":"Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies","volume":"21","author":"Bell","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz891","article-title":"Sudden cardiac death among persons with diabetes aged 1-49 years: a 10-year nationwide study of 14 294 deaths in Denmark","volume":"41","author":"Lynge","year":"2020","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/dom.14500","article-title":"Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection","author":"Andreasen","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/CIRCRESAHA.121.319874","article-title":"GLP1R attenuates sympathetic response to high glucose via carotid body inhibition","volume":"130","author":"Pauza","year":"2022","journal-title":"Circ Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1951.165.3.505","article-title":"Ventricular ectopic rhythms and ventricular fibrillation following cardiac sympathectomy and coronary occlusion","volume":"165","author":"Harris","year":"1951","journal-title":"Am J Physiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.113.302549","article-title":"Role of the autonomic nervous system in modulating cardiac arrhythmias","volume":"114","author":"Shen","year":"2014","journal-title":"Circ Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2804","article-title":"Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials","volume":"32","author":"Wang","year":"2016","journal-title":"Diabetes-Metab Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab724.2952","article-title":"Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias","volume":"42","author":"Boulmpou","year":"2021","journal-title":"Eur Heart J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-020-01546-0","article-title":"Diabetes increases the mortality of patients with COVID-19: a meta-analysis","volume":"58","author":"Wu","year":"2021","journal-title":"Acta Diabetol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2021.04.019","article-title":"Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: A systematic review, meta-analysis, and meta-regression","volume":"87","author":"Putri","year":"2021","journal-title":"Parkinsonism Relat D"},{"key":"B12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4102\/sajhivmed.v22i1.1220","article-title":"Human immunodeficiency virus and mortality from coronavirus disease 2019: A systematic review and meta-analysis","volume":"22","author":"Hariyanto","year":"2021","journal-title":"S Afr J HIV Med"},{"key":"B13","article-title":"Emergency medicine and social media - friends or foes","volume":"34","author":"Egea-Guerrero","year":"2022","journal-title":"Emergencias"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100312","DOI":"10.1016\/j.obmed.2020.100312","article-title":"Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment","volume":"22","author":"Pang","year":"2021","journal-title":"Obes Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-006-0094-9","article-title":"Lessons from SARS: control of acute lung failure by the SARS receptor ACE2","volume":"84","author":"Kuba","year":"2006","journal-title":"J Mol Med (Berl)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014-1685","article-title":"Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-a and SP-b in the lungs of type 1 diabetes rats","volume":"156","author":"Romani-Perez","year":"2015","journal-title":"Endocrinology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"109031","DOI":"10.1016\/j.diabres.2021.109031","article-title":"Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression","volume":"179","author":"Hariyanto","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj-Brit Med J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"New Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"New Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"New Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"New Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.7.1137","article-title":"Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients","volume":"22","author":"Toft-Nielsen","year":"1999","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1172\/JCI0215595","article-title":"Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons","volume":"110","author":"Yamamoto","year":"2002","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis","volume":"110","author":"Sun","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12843","article-title":"Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males","volume":"81","author":"Smits","year":"2016","journal-title":"Brit J Clin Pharmaco"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00153.2008","article-title":"Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans","volume":"295","author":"Bharucha","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04214.x","article-title":"Investigation of the haemodynamic effects of exenatide in healthy male subjects","volume":"74","author":"Mendis","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"101044","DOI":"10.1016\/j.molmet.2020.101044","article-title":"Diabetes, infection risk and COVID-19","volume":"39","author":"Erener","year":"2020","journal-title":"Mol Metab"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3094642","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-Based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediat Inflammation"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.609470","article-title":"Type 2 diabetes mellitus and COVID-19: A narrative review","volume":"12","author":"Corrao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.05.006","article-title":"Letter to the editor: Comment on GLP-1-based drugs and COVID-19 treatment","volume":"10","author":"Jin","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa011","article-title":"Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications","volume":"41","author":"Drucker","year":"2020","journal-title":"Endocr Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1666","article-title":"Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice","volume":"154","author":"Viby","year":"2013","journal-title":"Endocrinology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.11.043","article-title":"Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo","volume":"142","author":"Toki","year":"2018","journal-title":"J Allergy Clin Immun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/01.ccm.0000509615.06302.57","article-title":"Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice","volume":"44","author":"Zhang","year":"2016","journal-title":"Crit Care Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2016.10.016","article-title":"Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice","volume":"791","author":"Zhou","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.rmed.2019.06.015","article-title":"Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients","volume":"154","author":"Rogliani","year":"2019","journal-title":"Resp Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-010-0559-9","article-title":"GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats","volume":"382","author":"Ku","year":"2010","journal-title":"N-S Arch Pharmacol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.3390\/ijerph17103664","article-title":"Potential benefits and harms of novel antidiabetic drugs during COVID-19 crisis","volume":"17","author":"Mirabelli","year":"2020","journal-title":"Int J Env Res Pub He"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30152-2","article-title":"Practical recommendations for the management of diabetes in patients with COVID-19","volume":"8","author":"Bornstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.910256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T09:41:31Z","timestamp":1660210891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.910256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":48,"alternative-id":["10.3389\/fendo.2022.910256"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.910256","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"article-number":"910256"}}